相关实验视频

Updated: May 24, 2025

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

膝关节骨关节炎患者使用止痛药的模式:使用英国初级保健数据的队列研究

Aqila Taqi^1,2, Sonia Gran³, Roger David Knaggs^1,4,5

¹Division of Pharmacy Practice and Policy, School of Pharmacy, University Park Campus, University of Nottingham, Nottingham, UK.

Journal of pharmaceutical policy and practice

|March 3, 2025

概括

14.9%至36.8%的膝关节骨关节炎患者在一年内成为了持续使用止痛药的患者. 持续使用者更年轻,使用更高剂量,为未来的研究提供了关于长期结果的信息.

科学领域:

类风湿病学类风湿病学
药理学药理学是指药理学的学科.
公共卫生公共卫生

背景情况:

骨关节炎 (OA) 是一种广泛的致残关节疾病,在全球影响着超过3亿人,膝盖是受影响最常见的关节.
膝关节关节炎 (KOA) 通过疼痛,功能限制和降低生活质量显著影响患者,影响精神健康.
虽然止痛药在KOA患者中很常见,但关于使用模式的详细个体级数据仍然很少.

研究的目的:

描述膝关节骨关节炎 (KOA) 患者的止痛药使用模式.
确定KOA治疗开始后一年内持续使用者的比例.
为了比较持久与非持久止痛药使用者的特征.

主要方法:

一个回顾性队列研究利用了临床实践研究数据链接.
对发生KOA的成年人的止痛药处方进行了分析,分为五组:抗抑郁药,抗药 (AED),阿片类药物,NSAID和.
持续性被定义为每年使用>180个定义的每日剂量 (DDD),至少在四个季度中的三个季度处方.

主要成果:

不同比例的患者在不同类别的止痛药中持续使用了抗抑郁药:抗抑郁药 (36.8%),NSAID (27.0%),AED (23.8%),黄 (17.5%) 和阿片类药物 (14.9%).
与非持续使用者相比,持久使用者通常更年轻,获得更多的处方,并处方更高剂量的止痛药.
这些发现突显了KOA患者长期使用止痛药的显著差异.

结论:

14.9%至36.8%的KOA患者在处方后的第一年内转向持续止痛药的使用.
该研究确定了定义持续性的有意义的临床属性,这对未来的研究至关重要.
需要进一步研究不同类别止痛药的持续性与非持续性使用者的临床和不良药物结果.

关键词:

止痛药是一种止痛药.抗药物是一种抗药物.抗抑郁药是一种抗抑郁药.定义的每日剂量.持续使用持续使用.

更多相关视频

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Spontaneous and Evoked Measures of Pain in Murine Models of Monoarticular Knee Pain

Spontaneous and Evoked Measures of Pain in Murine Models of Monoarticular Knee Pain

Published on: February 22, 2019

相关概念视频

Analgesia and Pain Management

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...